Description
Rybelsus (semaglutide) is an oral GLP-1 receptor agonist listed in our GLP-1 and related medications directory and prescribed for type 2 diabetes (1.1) (2.1). Administered via the oral route, Rybelsus is available for delivery to U.S. residents through Canadian Pharmacy Store with a valid prescription. Review the clinical fact table, dosage directions, cautions, drug interactions, side effects, and official regulatory sources below.
Rybelsus is a medication containing the active pharmaceutical ingredient semaglutide, classified pharmacologically as an oral GLP-1 receptor agonist (2.1). It is clinically indicated for the management of type 2 diabetes as part of a comprehensive treatment plan supervised by a licensed healthcare provider (2.1).
Within the GLP-1 and related medications section of our catalogue, patients and prescribers frequently review Rybelsus alongside related therapies such as Ozempic (Semaglutide), Wegovy (Semaglutide), Mounjaro (Tirzepatide), and Saxenda (Liraglutide).
Official Indications and Usage
And Ozempic tablets are indicated (1.1):
- As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- To reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.
Mechanism of Action and Pharmacology
Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors. The principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation. Furthermore, semaglutide is stabilized against degradation by the DPP-4 enzyme. (1.1) (3.1)
What is Type 2 diabetes?
Type 2 diabetes involves high blood glucose because the body does not use insulin effectively and may not make enough. Treatment depends on individual glucose, heart, kidney, and other health needs. Explore related medications below and discuss treatment options with your healthcare provider. Read our complete Type 2 diabetes condition guide for appointment questions and related therapies (4.1).
Ordering Rybelsus from Canada for U.S. Delivery
U.S. patients can order Rybelsus (Semaglutide) in U.S. dollars with a valid prescription from a U.S.-licensed clinician. Your card is only charged after your prescription passes pharmacist safety checks and is ready to ship.
Step 1
Send Your Prescription
- Valid Rx required from a U.S.-licensed physician, NP, or PA (Rx rules).
- Upload Rx online, request a pharmacy transfer, or have your doctor fax (844) 666 – 6819.
- Order up to a 90-day personal-use supply per shipment (refill planning).
Step 2
Pharmacist Safety Check
- Multi-point dosing and interaction review completed in under 1 business day.
- Mandatory licensed pharmacist consultation via phone, voicemail, or text before dispatch.
- Verified under our Pharmacy Safety Standards.
Step 3
$14.99 USD Tracked Parcel
- Packed in discreet protective packaging for a flat $14.99 USD per order ($29.99 if combined with cold-chain).
- Tracked via Canada Post and USPS: 3 to 7 business days from Canada (7 to 14 days from international partners).
- Review full shipping and delivery details.
Step 4
U.S. Street Delivery & Payment
- Delivered to any physical U.S. street address with signature upon delivery (no P.O. Boxes).
- You see and approve the country of origin upfront before your card is charged.
- Report any delayed or damaged parcel within 48 hours for prompt resolution.
Fact Table
| Clinical Specification | Details |
|---|---|
| Brand / Product Name | Rybelsus |
| Chemical / Generic Name | Semaglutide |
| Pharmacological Class | Oral GLP-1 receptor agonist |
| Therapeutic Category | GLP-1 and related medications |
| Same-Ingredient Catalogue Entries | Ozempic (Semaglutide), Wegovy (Semaglutide) |
| Molecular Formula | C187H291N45O59 (3.1) |
| Molecular Weight | 4114 g/mol (3.1) |
| Bioavailability | ~0.4% (1.1) |
| Legal Status | Rx-Only (Prescription Required) |
| Regulatory Reference Authorities | U.S. FDA (DailyMed), Health Canada (DPD), NIH PubChem, NLM MedlinePlus |
| Routes of Administration | Oral |
| Available Dosage Strengths | 1.5mg, 4mg, 9mg |
| Dosage Form | Tablet |
| Primary Indications | Type 2 Diabetes |
| Pregnancy & Breastfeeding | Consult Doctor / Prescriber before use |
| PubChem CID | 56843331 |
| FDA UNII Identifier | 53AXN4NNHX |
| NLM RxNorm Concept ID (RxCUI) | 2200644, 2200650, 2200652, 2200654 |
| FDA Application License | NDA213051 |
| Official DailyMed SetID | 27f15fac-7d98-4114-a2ec-92494a91da98 |
| Catalogue Index Links | Letter R Index · All Medications · All Categories |
Directions
Dosage and Administration Overview
- Rybelsus and Ozempic tablets are not substitutable on a mg-to-mg basis.
- Take Rybelsus or Ozempic tablets orally once daily on an empty stomach in the morning with water (up to 4 ounces of water); do not take with other liquids besides water.
- Swallow tablets whole. Do not split, crush, chew or dissolve in any solution.
- After taking Rybelsus or Ozempic tablets, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications.
- See the Full Prescribing Information for instructions on switching between Rybelsus and Ozempic tablets and from Ozempic injections to Rybelsus or Ozempic tablets. Recommended Starting, Escalation and Maintenance Dosage of Rybelsus and Ozempic Tablets Rybelsus.
- Day 1 to 30: Recommended starting dosage is 3 mg orally once daily for 30 days (this dosage is not effective for glycemic control).
- On Day 61 or thereafter, if:
- No additional glycemic control is needed, maintain the dosage at 7 mg orally once daily. (1.1)
Presentations and Strengths
Rybelsus (semaglutide) tablets are available as (1.1):
- 3 mg: white to light yellow, oval shaped debossed with “3” on one side and “novo” on the other side.
Administration Guidance
Take Rybelsus orally at the same time(s) each day as directed on your prescription label (1.1). Check with your pharmacist whether your specific formulation should be taken with a meal or on an empty stomach, and swallow extended-release or film-coated tablets whole without crushing, chewing, or splitting unless the tablet is scored and your prescriber has instructed you to do so.
Missed Dose Guidance
If you miss a scheduled dose of Rybelsus, follow the missed-dose instructions in the official patient leaflet or ask your pharmacist. Do not double the next dose to make up for a missed dose (2.1).
Ingredients
Active Pharmaceutical Ingredient
The active ingredient in Rybelsus is semaglutide (molecular formula C187H291N45O59, molecular weight 4114 g/mol) (1.1) (3.1). Other catalogue entries containing semaglutide include Ozempic (Semaglutide) and Wegovy (Semaglutide).
Inactive Ingredients (Excipients)
According to the U.S. FDA product labeling, formulation excipients include magnesium stearate, microcrystalline cellulose, povidone and salcaprozate sodium (snac) (1.1). Inactive ingredients can vary slightly between different manufacturers and international or generic presentations; review the dispensed carton if you have known excipient sensitivities.
Cautions and important safety information
Boxed Warning
Warning: risk of thyroid C-cell tumors (1.1):
- In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Rybelsus and Ozempic tablets cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
- Rybelsus and Ozempic tablets are contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Contraindications
And Ozempic tablets are contraindicated in patients with (1.1):
- A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- A prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Rybelsus or Ozempic tablets. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with semaglutide tablets.
Key Clinical Precautions
Before starting or continuing Rybelsus, discuss your complete medical history with your healthcare provider. Key clinical cautions include (1.1):
- Risk of thyroid C-cell tumors: In rodent studies, certain incretin and GLP-1 receptor agonists caused thyroid C-cell tumors. This class is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Hypoglycemia (low blood sugar): When used alongside insulin therapies or insulin secretagogues (such as sulfonylureas), the risk of hypoglycemia increases. Patients may need a lower dose of their secretagogue or insulin and should recognize symptoms like shakiness, sweating, fast heartbeat, dizziness, and confusion.
- Acute pancreatitis: Persistent, severe abdominal pain, sometimes radiating to the back and accompanied by vomiting, can indicate acute pancreatitis. Discontinue therapy and contact your clinician promptly if these symptoms develop.
- Hypersensitivity and anaphylaxis: Serious allergic reactions, including anaphylaxis, angioedema, and severe rash, have been reported. Discontinue use and seek immediate medical care if swelling of the face, lips, tongue, or throat or difficulty breathing occurs.
- Angioedema: Swelling of the face, extremities, lips, tongue, glottis, or larynx can occur at any time during treatment. Airway-involving angioedema requires emergency medical intervention.
- Renal function and acute kidney injury: Changes in serum creatinine or estimated glomerular filtration rate (eGFR) can occur, particularly in patients with volume depletion, chronic kidney disease, or concomitant use of NSAIDs, ACE inhibitors, ARBs, or diuretics. Renal function should be assessed prior to initiation and periodically thereafter.
Pregnancy, Lactation, and Special Populations
Available data with semaglutide use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. There are clinical considerations regarding the risks of poorly controlled diabetes in pregnancy. Based on animal reproduction studies, there may be potential risks to the fetus from exposure to semaglutide during pregnancy. Rybelsus or Ozempic tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. (1.1)
Interactions
Official Drug Interaction Overview
Other Oral Drugs: Rybelsus and Ozempic tablets delay gastric emptying. Consider increased clinical or laboratory monitoring when co-administered with other oral medications that have a narrow therapeutic index or that require clinical monitoring. (1.1)
Important Interaction Categories
Concomitant use of Rybelsus with certain prescription medications, over-the-counter drugs, or supplements can alter how the medication works or increase the risk of side effects. Important interaction categories to review with your prescriber and pharmacist include (2.1):
- Insulin and insulin secretagogues (such as sulfonylureas including Amaryl (Glimepiride), Glucotrol XL (Glipizide), or DiaBeta (Glyburide), as well as insulin preparations): Concomitant use can increase the risk of hypoglycemia (low blood sugar). Your prescriber may recommend blood glucose monitoring or a dose adjustment of your insulin or secretagogue.
Side effects
Like all medications, Rybelsus can cause side effects, although not everyone experiences them. Commonly reported side effects in clinical trials and official labeling include (1.1):
- Nausea (feeling sick): Often mild to moderate and most noticeable when starting therapy or increasing the dose; note that Rybelsus must be taken on an empty stomach with no more than 4 oz of plain water at least 30 minutes before the first food, beverage, or other oral medications of the day; eating smaller, low-fat meals later in the day may help reduce nausea.
- Vomiting: Persistent vomiting that prevents fluid intake should be reported to your clinician to prevent dehydration.
- Diarrhea (loose stools): Maintain adequate fluid and electrolyte intake; contact your prescriber if diarrhea is severe or persistent.
- Constipation: Adequate hydration and dietary fiber can help manage mild changes in bowel habits.
- Headache: Commonly reported during initial treatment; often improves as your body adjusts to the medication.
- Dizziness or lightheadedness: May occur especially when standing up quickly from a sitting or lying position (orthostatic changes); rise slowly and stay well hydrated.
Clinical Trial and Postmarketing Adverse Reactions
The following serious adverse reactions are described below or elsewhere in the prescribing information (1.1):
- Risk of Thyroid C-cell Tumors.
- Acute Pancreatitis.
- Diabetic Retinopathy Complications.
- Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin.
- Acute Kidney Injury Due to Volume Depletion.
- Severe Gastrointestinal Adverse Reactions.
- Hypersensitivity Reactions.
- Acute Gallbladder Disease.
- Pulmonary Aspiration During General Anesthesia or Deep Sedation Most common adverse reactions (incidence ≥5%) are nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation.
When to Seek Immediate Medical Attention
Contact your physician or seek urgent medical care if you experience signs of a severe allergic reaction (hives, difficulty breathing, or swelling of the face, lips, tongue, or throat), severe dizziness or fainting, unexplained severe pain, or any sudden change in your clinical symptoms (2.1).
Storage and handling
Rybelsus strengths are available as follows: Tablet Strength Description Package Configuration NDC Number 3 mg White to light yellow, oval shaped debossed with “3” on one side and “novo” on the other side Bottle of 30 tablets 0169-4303-30 7 mg White to light yellow, oval shaped debossed with “7” on one side and “novo” on the other side Bottle of 30 tablets 0169-4307-30 14 mg White to light yellow, oval shaped debossed with “14” on one side and “novo” on the other side Bottle of 30 tablets 0169-4314-30 Ozempic tablet strengths are available as follows: Tablet Strength Description Package Configuration NDC Number 1.5 mg White to light yellow, round shaped debossed with “1.5” on one side and “novo” on the other side Bottle of 30 tablets 0169-1715-30 4 mg White to light yellow, ro. (1.1)
Store Rybelsus in its original container at controlled room temperature away from excess heat, direct light, and moisture (such as bathroom cabinets), and keep out of reach of children and pets (1.1).
What is a generic drug?
A generic medication contains the exact same active pharmaceutical ingredient (semaglutide) as its brand-name counterpart and is formulated to deliver the same dosage strength, route of administration, safety profile, quality, and therapeutic performance (2.1). Regulatory authorities require generic manufacturers to demonstrate bioequivalence, meaning the generic medication releases its active ingredient into the bloodstream at virtually the same rate and to the same extent as the innovator brand.
While a generic tablet, capsule, or inhaler may differ in color, shape, scoring, or packaging due to trademark laws that govern brand appearance, its clinical mechanism and active ingredient match the reference medicine. Because generic manufacturers do not repeat the initial discovery and multi-phase clinical trial investments of the original brand, generic equivalents offer substantial cost savings for patients paying out of pocket.
Canadian Pharmacy Store delivers prescription and over-the-counter medications to U.S. residents. Browse our GLP-1 and related medications directory, explore all medications A-Z, review how ordering works and prescription requirements, or call 1-888-868-1920 for personal assistance matching your prescription.
Related Medications in Our Catalogue
- Ozempic (Semaglutide), listed in GLP-1 and related medications
- Wegovy (Semaglutide), listed in GLP-1 and related medications
- Mounjaro (Tirzepatide), listed in GLP-1 and related medications
- Saxenda (Liraglutide), listed in GLP-1 and related medications
- Trulicity (Dulaglutide), listed in GLP-1 and related medications
- Zepbound (Tirzepatide), listed in GLP-1 and related medications
Related Categories, Directories, and Ordering Guides
- GLP-1 and related medications Category Directory
- Medications Starting with R
- Active Ingredient Directory
- Rybelsus vs. Ozempic injection: semaglutide presentations
- Does semaglutide need refrigeration? Check the exact product
- Ozempic, Mounjaro, Wegovy and Zepbound: product differences
- How to Order Prescription Medication
- Prescription Requirements
- Shipping and Delivery to the U.S.
- How to Compare Prescription Prices
- Contact Customer & Pharmacy Support
- Explore Medications
- Explore Categories
- Explore Diabetes
- Explore Amaryl Glimepiride
- Explore Glucotrol Xl Glipizide
- Explore Diabeta Glyburide
Frequently Asked Questions About Rybelsus
What is Rybelsus and what active ingredient does it contain?
Rybelsus is an oral GLP-1 receptor agonist containing the active pharmaceutical ingredient semaglutide (chemical formula C187H291N45O59). It is supplied for oral administration and requires a valid prescription where applicable.
How does Rybelsus work in the body?
Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors.
What conditions is Rybelsus prescribed to treat?
Rybelsus is primarily indicated for type 2 diabetes. Your prescribing clinician determines the appropriate indication, strength, and treatment duration based on your individual diagnosis and medical history.
How should I take or use Rybelsus?
Follow the exact dosage, frequency, and administration instructions printed on your prescription label. Rybelsus is administered via the oral route. Take it consistently at the same time(s) as directed, and never adjust your dose or stop therapy without speaking with your prescriber.
What are the most common side effects of Rybelsus?
Commonly reported side effects of Rybelsus include feeling sick, vomiting, loose stools, constipation, headache, and dizziness. Most mild side effects improve as your body adjusts to treatment, but you should notify your doctor or pharmacist if symptoms persist or worsen.
What medications or substances can interact with Rybelsus?
Important interaction categories for Rybelsus include insulin. Always share a complete list of your prescription drugs, over-the-counter medicines, vitamins, and herbal supplements with your pharmacist before starting treatment.
Can Rybelsus be used during pregnancy or breastfeeding?
If you are pregnant, planning to become pregnant, or breastfeeding, consult your prescribing physician before using Rybelsus to weigh the clinical benefits and potential risks.
Do I need a prescription to buy Rybelsus online from Canada?
Yes. A valid prescription written by a U.S.-licensed physician, nurse practitioner, or physician assistant is required to buy Rybelsus (Semaglutide) through our licensed Canadian pharmacy partners. Valid prescriptions go through multiple safety checks in less than 1 business day, followed by a mandatory request to speak with a licensed pharmacist for a consultation (watch your phone, voicemails, and text messages).
Does Rybelsus have a generic equivalent (Semaglutide) at a Canada pharmacy?
Yes. A lower-cost generic equivalent (Semaglutide) containing Semaglutide is available alongside brand-name Rybelsus in our Canada pharmacy catalogue.
Other Brands: Ozempic, WegovyGeneric: Semaglutide
How is Rybelsus shipped to U.S. residents, and how much does shipping cost?
Rybelsus ships in discreet protective packaging at a flat rate of $14.99 USD per order via Canada Post and USPS with full tracking (if combined in the same order with a cold-chain item, total shipping is $29.99 USD in a larger container). Once your valid prescription passes safety checks (<1 business day) and you respond to the mandatory licensed pharmacist consultation request via phone, voicemail, or text message, delivery takes 3 to 7 business days from Manitoba, Canada (or 7 to 14 business days from licensed partner pharmacies in the UK, Singapore, and Mauritius). You see and choose the country of origin before you pay, and your Visa, Mastercard, or Discover card is only charged when your order is ready to ship.
How can I send or transfer my Rybelsus prescription, or ask about an unlisted strength?
You can upload a clear photo or PDF of your Rybelsus prescription online, request a prescription transfer or direct prescriber coordination from our team, or have your prescriber fax the prescription directly to (844) 666 – 6819. You may order up to a 90-day personal-use supply per shipment. If you do not see your exact prescribed strength or manufacturer listed, call 1-888-868-1920 and our staff will check availability across our licensed pharmacy partners.
References & Official Sources
Clinical, pharmacological, and safety facts for Rybelsus (Semaglutide) are compiled directly from official regulatory prescribing labels and primary biomedical databases:
- (1.1) Ozempic (Oral semaglutide) tablet Rybelsus (Oral semaglutide) tablet [novo nordisk pharmaceutical industries, LP]. U.S. National Library of Medicine / U.S. Food and Drug Administration (DailyMed). Official U.S. FDA / DailyMed Structured Product Labeling (SPL). (Accessed 2026-10-29).
- (2.1) Health Canada Drug Product Database (DPD), Authorized Product Records. Health Canada / Government of Canada. Health Canada Drug Product Database & Official Product Monograph. (Accessed 2026-10-28).
- (3.1) PubChem Compound Summary for cid 56843331 (Semaglutide). National Center for Biotechnology Information (NCBI), U.S. National Library of Medicine. Official regulatory & clinical reference. (Accessed 2026-10-29).
- (4.1) MedlinePlus Medical Encyclopedia: Diabetes Type 2. MedlinePlus / National Library of Medicine. U.S. National Library of Medicine, MedlinePlus Drug & Health Information. (Accessed 2026-10-29).
